<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01278290</url>
  </required_header>
  <id_info>
    <org_study_id>HNinosBuenosAires-Triptorelin</org_study_id>
    <nct_id>NCT01278290</nct_id>
  </id_info>
  <brief_title>Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls</brief_title>
  <official_title>Triptorelin Acetate Utilization for the Early Diagnosis of Central Precocious Puberty (CPP) in Girls.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Niños R. Gutierrez de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Niños R. Gutierrez de Buenos Aires</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the specificity, sensitivity and diagnostic efficiency
      of the Triptorelin Test in the assessment of CPP compared to GnRH test as gold standard.

      Hypothesis: Aqueous Triptorelin Acetate is so efficient as GnRH to CPP assessment.

      Study population are girls with suspicious clinical features of precocious puberty
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GnRH stimulation is the gold standard to distinguish between isolated premature thelarche
      (PT) and CPP. However, intravenous GnRH for testing is not fully available in all countries.
      To evaluate the diagnostic accuracy of a novel Triptorelin-test in the assessment of CPP
      compared to the GnRH test, a validation study was performed. Girls who presented thelarche
      with accelerated growth and/or advanced bone age were included. All girls underwent the two
      tests in a randomized order. CPP was ascertained according to LH response under GnRH (gold
      standard test).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LH</measure>
    <time_frame>3 hs</time_frame>
    <description>Levels of LH are measured at T 0 (before) and T 3 h y T 24 h (after) Triptorelin stimulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estradiol</measure>
    <time_frame>24 hs</time_frame>
    <description>Levels of Estradiol are measured at T 0 (before) and T 3 h y T 24 h (after) Triptorelin stimulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FSH</measure>
    <time_frame>3 hs</time_frame>
    <description>Levels of FSH are measured at T 0 (before) and T 3 h y T 24 h (after) Triptorelin stimulation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Central Precocious Puberty</condition>
  <condition>Sexual Precocity</condition>
  <arm_group>
    <arm_group_label>Triptorelin test AND LHRH test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo two tests with a test interval of at least 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LHRH test AND Triptorelin test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo two test with a test interval of al least 15 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin acetate and Gonadorelin acetate</intervention_name>
    <description>Triptorelin acetate aqueous 0.1 mg/m2 subcutaneous. Gonadorelin acetate 100 ug intravenous.</description>
    <arm_group_label>Triptorelin test AND LHRH test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadorelin acetate and Triptorelin acetate</intervention_name>
    <description>Gonadorelin acetate intravenous 100 ug. Triptorelin acetate 100 ug/m2.</description>
    <arm_group_label>LHRH test AND Triptorelin test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premature thelarche and/or

          -  accelerated growth velocity (above 90 percentile)

          -  advanced bone age at least 1.5 year in relation to chronological age.

        Exclusion Criteria:

          -  contact with sources of exogenous estrogens in the last four months previous to
             evaluation,

          -  suspicion of peripheral precocious puberty,

          -  previous central nervous system illness or suspicion of organic central precocious
             puberty.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria G Ropelato, PhD</last_name>
    <role>Study Director</role>
    <affiliation>División de Endocrinología, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Analía V Freire, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>División de Endocrinología, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Niños Ricardo Gutierrez, División de Endocrinología</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>C1425SEFD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>January 14, 2011</last_update_submitted>
  <last_update_submitted_qc>January 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Analía Freire, MD, María Gabriela Ropelato, PhD.</name_title>
    <organization>Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.</organization>
  </responsible_party>
  <keyword>Triptorelin acetate</keyword>
  <keyword>precocious puberty</keyword>
  <keyword>premature thelarche</keyword>
  <keyword>GnRH analog</keyword>
  <keyword>Diagnostic validation study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puberty, Precocious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

